This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

AstraZeneca Yönetim

Yönetim kriter kontrolleri 3/4

AstraZeneca CEO'su Pascal Claude Soriot, Oct2012 tarihinde atandı, in görev süresi 13.33 yıldır. in toplam yıllık tazminatı $ 18.44M olup, şirket hissesi ve opsiyonları dahil olmak üzere 10.1% maaş ve 89.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.016% ine doğrudan sahiptir ve bu hisseler $ 47.94M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 8.6 yıl ve 7.7 yıldır.

Anahtar bilgiler

Pascal Claude Soriot

İcra Kurulu Başkanı

US$18.4m

Toplam tazminat

CEO maaş yüzdesi	10.09%
CEO görev süresi	13.3yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	8.6yrs
Yönetim Kurulu ortalama görev süresi	7.7yrs

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • Jan 10

AstraZeneca: Oncology Dominance Justifies New All-Time Highs

Summary AstraZeneca started 2026 on a high note. On January 7, its stock reached an all-time high of $95.94. The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular franchises. For example, sales of Tagrisso, an EGFR inhibitor for the treatment of people with non-small cell lung cancer, reached $1.86 billion in Q3, up 11.4% year-on-year. And coupledwith significant progress in its baxdrostat and blockbuster therapy Imfinzi, Icontinue to cover AstraZeneca with a 'Buy' rating. Read the full article on Seeking Alpha

Seeking Alpha • Mar 05

AstraZeneca: A Big Pharma Blue Chip To Buy Now

Summary AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. The company is well-positioned for growth over the next few years. AstraZeneca's net debt-to-adjusted EBITDA ratio improved to just 1.5x in 2024. Shares of the drugmaker appear to be priced 14% below fair value. AstraZeneca could be set up to generate 15% annual total returns through 2027. Read the full article on Seeking Alpha

CEO Tazminat Analizi

Pascal Claude Soriot'un ücretlendirmesi AstraZeneca'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2025	n/a	n/a	US$9b
Jun 30 2025	n/a	n/a	US$8b
Mar 31 2025	n/a	n/a	US$8b
Dec 31 2024	US$18m	US$2m	US$7b
Sep 30 2024	n/a	n/a	US$6b
Jun 30 2024	n/a	n/a	US$6b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$22m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$5b
Dec 31 2022	US$18m	US$2m	US$3b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	-US$1b
Mar 31 2022	n/a	n/a	-US$1b
Dec 31 2021	US$21m	US$2m	US$112m
Sep 30 2021	n/a	n/a	US$1b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$4b
Dec 31 2020	US$22m	US$2m	US$3b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$20m	US$2m	US$1b

Tazminat ve Piyasa: Pascal Claude 'nin toplam tazminatı ($USD 18.44M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 14.79M ).

Tazminat ve Kazançlar: Pascal Claude 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Pascal Claude Soriot (66 yo)

13.3yrs

Görev süresi

US$18,439,041

Tazminat

Mr. Pascal Claude Roland Soriot, M.B.A., D.V.M., is Director of Agilent Technologies, Inc. from May 21, 2025. He has been the Chief Executive Officer and Executive Director at AstraZeneca PLC since October...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Pascal Claude Soriot	CEO & Executive Director	13.3yrs	US$18.44m	0.016% $ 47.9m
Aradhana Sarin	CFO & Executive Director	4.5yrs	US$8.45m	0.0069% $ 20.5m
Pam Cheng	EVP of Global opt. & IT	10.7yrs	Veri yok	Veri yok
Andrew Barnett	Head of Investor Relations	no data	Veri yok	Veri yok
Jeffrey Pott	CHRO, Chief Compliance Officer	17.1yrs	Veri yok	Veri yok
Ruud Dobber	Executive Vice-President of BioPharmaceuticals Business Unit	13.1yrs	Veri yok	Veri yok
Susan Galbraith	Executive Vice President of Oncology R&D	no data	Veri yok	Veri yok
Iskra Reic	Executive Vice President of International	8.8yrs	Veri yok	Veri yok
David Fredrickson	Executive Vice-President of Oncology Haematology Business Unit	8.3yrs	Veri yok	Veri yok
Ruth March	Senior VP of Precision Medicine - R&D Oncology	7.1yrs	Veri yok	Veri yok
Joris Silon	President of Bio Pharmaceutical Business Unit - US	7.2yrs	Veri yok	Veri yok
Lutz Jermutus	Head of Projects	6.7yrs	Veri yok	Veri yok

8.6yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: AZN 'un yönetim ekibi deneyimli ve deneyimlidir ( 8.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Pascal Claude Soriot	CEO & Executive Director	13.3yrs	US$18.44m	0.016% $ 47.9m
Aradhana Sarin	CFO & Executive Director	4.5yrs	US$8.45m	0.0069% $ 20.5m
Pam Cheng	EVP of Global opt. & IT	no data	Veri yok	Veri yok
Jeffrey Pott	CHRO, Chief Compliance Officer	no data	Veri yok	Veri yok
Marcus Wallenberg	Non-Executive Director	26.8yrs	US$194.06k	0.0039% $ 11.5m
Philip John Broadley	Senior Independent Non-Executive Director	8.8yrs	US$291.71k	0.00052% $ 1.5m
Diana Louise Layfield	Independent Non-Executive Director	5.3yrs	US$169.02k	0.000090% $ 267.8k
Michel Demare	Independent Chairman	6.4yrs	US$1.00m	0.00064% $ 1.9m
Sherilyn S. McCoy	Independent Non-Executive Director	8.3yrs	US$256.65k	0.00011% $ 327.3k
Euan Ashley	Independent Non-Executive Director	5.3yrs	US$200.32k	0.00010% $ 297.6k
Shu Kam Mok	Independent Non-Executive Director	7.1yrs	US$169.02k	0.00023% $ 684.4k
Sabera Rahman	Independent Non-Executive Director	8.7yrs	US$250.39k	0.000050% $ 148.8k

7.7yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AZN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.7 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/02/03 00:50
Gün Sonu Hisse Fiyatı	2026/01/30 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

AstraZeneca PLC 60 Bu analistlerden 24, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
null null	ABG Sundal Collier
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research

This company listing is no longer active

AstraZeneca Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

AstraZeneca Appoints Rick R. Suarez As Senior Vice President, US President, And Head Of US BioPharmaceuticals Business Unit

AstraZeneca PLC Appoints Karen Knudsen as Director

Recent updates

AstraZeneca PLC (LSE:AZN) agreed to acquire remaining 50% stake in China rights to GPC3 armored CAR-T therapy from Abelzeta Inc. for $630 million.

European Medicines Agency Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

AstraZeneca PLC (LSE:AZN) acquired Modella AI, Inc.

TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

AstraZeneca: Oncology Dominance Justifies New All-Time Highs

AstraZeneca Appoints Rick R. Suarez As Senior Vice President, US President, And Head Of US BioPharmaceuticals Business Unit

Astrazeneca and Enhertu Announce that it has Been Granted Breakthrough Therapy Designation in the US for Adult Patients with Her2-Positive Early Breast Cancer with Residual Invasive Disease in the Breast And/Or Axillary Lymph Nodes After Neoadjuvant Treatment and High Risk of Disease Recurrence

Daiichi Sankyo and AstraZeneca's DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy

Astrazeneca and Daiichi Sankyo's ENHERTU®? (Fam-Trastuzumab Deruxtecan-nxki) Approves in the US as First New Treatment in A decade for the 1st-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer

AstraZeneca PLC Advances Hematology and Cell Therapy Ambition with Largest-Ever Presence at ASH

AstraZeneca's New Drug Application Accepted Under FDA Priority Review in the US for Patients with Hard-To-Control Hypertension

AstraZeneca plc Announces Approval in the US for First and Only Perioperative Immunotherapy for Patients with Early Gastric and Gastroesophageal Cancers

Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib) Approves in the US

AstraZeneca Announces Positive Full Results from the Bax24 Phase III Trial

AstraZeneca PLC Reiterates Earnings Guidance for 2025

DESTINY-Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Small Cell Lung Cancer

AstraZeneca PLC Announces Koselugo Approved in the EUfor Plexiform Neurofibromas in Adults with Neurofibromatosis Type 1

AstraZeneca and Amgen's Tezepelumab Approves in the European Union

Daiichi Sankyo and AstraZeneca Announces Positive Results from the TROPION-Breast02 Phase 3 Trial

AstraZeneca and Amgen's Tezepelumab Approves in the US for Chronic Rhinosinusitis with Nasal Polyps

AstraZeneca, Inc. Announces Positive Results from the Matterorn Phase III Trial

AstraZeneca Furthers ambition to Redefine Cancer Care with First Data from Four Major Pivotal Trials at ESMO

AstraZeneca PLC Announces Baxdrostat Met Primary Endpoints in Bax24 Phase Iii Trial in Patients with Resistant Hypertension

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from the TROPION-Breast02 Phase III Trial

Daiichi Sankyo and Astrazeneca's Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk Her2 Positive Early-Stage Breast Cancer Prior to Surgery

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from Planned Interim Analysis of the DESTINY-Breast05 Phase III Trial

AstraZeneca Launches Direct-To-Consumer Platform to Expand Access to Medications for US Patients, Including Those Living with Chronic Conditions

Daiichi Sankyo and AstraZeneca's Supplemental Biologics License Application for Enhertu®? in Combination with Pertuzumab Deruxtecan-nxki

AstraZeneca PLC Announces European Medicines Agency Recommends Koselugo for the Treatment of Plexiform Neurofibromas in Adult Patients

AstraZeneca, Inc. Provides Update on A Supplemental New Drug Application (sNDA) for Airscra

AstraZeneca plc Announces Saphnelo Met Primary Endpoint in TULIP-SC

ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors

AstraZeneca Announces Positive Results from the Final Overall Survival Analysis of the FLAURA2 Phase III Trial

AstraZeneca Launches FluMist Home, At-Home Delivery Service for FLUMIST

Astrazeneca Canada Inc. Announces Approval in Canada as First and Only Perioperative Immunotherapy for Muscle Invasive Bladder Cancer

AstraZeneca PLC Reiterates Earnings Guidance for the Fiscal Year 2025

AstraZeneca PLC Announces Positive Results from PrevaIL Phase III Trial

AstraZeneca Announces Positive High-Level Results from the Final Overall Survival Analysis of the FLAURA2 Phase III Trial

Alexion Announces Update on CARES Phase III Clinical Programme of Anselamimab in Light Chain Amyloidosis

AstraZeneca plc Announces Baxdrostat Met the Primary and All Secondary Endpoints in BaxHTN Phase III Trial in Patients with Undunded or Treatment Resistant Hypertension

European Union Approves Imfinzi®? (Durvalumab) for the Treatment of Adult Patients with Resistant Muscle-Invasive Bladder Cancer

Datroway Approves in Us for EGFRm Lung Cancer

AstraZeneca plc Announces Fixed-Term Calquence Approval in EU for 1L CLL

AstraZeneca and Daiichi Sankyo’S ENHERTU Plus Pertuzumab Showed A Median Progression-Free Survival Greater Than Three Years

Astrazeneca's Imfinzi Recommends for Approval in the Eu by Chmp as First and Only Perioperative Immunotherapy for Muscle-Invasive Bladder Cancer

Health Canada Grants Notice of Compliance with Conditions for Tagrisso (Osimertinib) for the Treatment of Patients with Locally Advanced, Unresectable (Stage Iii) Non-Small Cell Lung Cancer

AstraZeneca 's Record Seventh Year of Plenary Data At Asco Furthers Ambition to Redefine Breast Cancer Care and Transform Outcomes in Gastric Cancer

AstraZeneca PLC (LSE:AZN) completed the acquisition of EsoBiotec B.V.

Astrazeneca to Showcase Latest Research on Comprehensive Portfolio and Pipeline Aimed At Transforming Respiratory Diseases At ATS 2025

AstraZeneca’s IMFINZI® (durvalumab) Regimen Demonstrates Statistically Significant and Clinically Meaningful Improvement in Disease-Free Survival for High-Risk Non-Muscle-Invasive Bladder Cancer in Potomac Phase III Trial

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from the DESTINY-Breast11 Phase III Trial

Astrazeneca Met Primary Endpoints in Kalos and Logos Phase Iii Trials in Asthma

AstraZeneca PLC to Report Q2, 2025 Results on Jul 29, 2025

Enhertu Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

AstraZeneca PLC Appoints Karen Knudsen as Director

Daiichi Sankyo and AstraZeneca Announce European Union Approves DATROWAY®? for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

AstraZeneca PLC Approves Imfinzi in Eu for AEGEAN

AstraZeneca’s AZD0780 Demonstrates Significant LDL Cholesterol (LDL-C) Reduction in Pursuit Phase IIb Trial

IgniteData Advances Clinical Trial Efficiencies with Successful Deployment at Leading Cancer Center

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca

AstraZeneca PLC Announces Eneboparatide Met Primary Endpoint of Normalising Seric Calypso Trial Continues as Planned to 52 Weeks to Further Characterise the Risk-Benef Benefit Profile

Ionis Pharmaceuticals, Inc. and Astrazeneca’s WAINZUA (eplontersen) Approves in the EU for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults with Stage 1 or Stage 2 Polyneuropathy

AstraZeneca PLC Announces Positive High-Level Results from the Matterhorn Phase III Trial